STOCKSCOUTER

StockScouter Premium

StockScouter Screener and Portfolios are now in our premium offering.
Learn more or Get it now! Stockscouter Portfolio performance

ITCI INTRA CELLULAR THERAPIES INCORPORATED StockScouter® Report

4

StockScouter® Score

INTRA CELLULAR THERAPIES INCORPORATED, a mid cap growth company in the healthcare sector, is expected to slightly outperform the market over the next six months with average risk

10 is the best possible rating. Learn more.

Summary

Positives

  • Earnings growth in the past year has accelerated moderately compared to earnings growth in the past three years. Positive
  • The most recent quarterly earnings report higher than analysts’ consensus forecast. Positive

 

Concerns

  • The enterprise value-to-sales ratio is much higher than the average for comparably-sized companies in the StockScouter universe. Very Negative
  • Two or more executives, board directors or major shareholders – including one high-level executive -- sold a large number of shares recently. Very negative

 

Short-term Outlook

Over the next 1-2 months, StockScouter forecasts that mid cap stocks will be out of favor, growth stocks will be out of favor, and healthcare stocks will be out of favor.

Expected Risk/Return

Progress: 60% done.
Progress: 80% done.
Low
High

Core Model Grades

B
F
F
C

Previous Ratings

3
5
5